Loading…
Loading…
NervGen Pharma remains a Buy, with reduced regulatory, financing, and execution risks following FDA alignment on the Phase 3 RESTORE trial. NGEN's recent $60M capital raise secures funding for its pivotal trial, shifting focus to NVG-291's ability to replicate efficacy in chronic tetraplegia. Objective biomechanical gait analysis showed statistically significant improvements, reinforcing the case for NVG-291's neural recovery over compensatory adaptation.
I describe a pair trade opportunity between Nuveen AMT-Free Municipal Credit Income Fund and Nuveen Municipal Credit Income Fund to exploit current mispricing. NVG and NZF have very similar, highly correlated portfolios, minimizing credit and duration risk in a paired position. Currently, NZF trades at a premium while NVG is at NAV, diverging from historical discount relationships and presenting a mean reversion opportunity.
Nuveen AMT-Free Municipal Credit Income Fund now trades at a slight premium, continuing the trend of tighter valuation. NVG's 7.48% yield is high and getting investors' attention, but it continues to remain significantly undercovered. I would continue to avoid NVG, though it has done incredibly well thanks to going to a premium.
VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced positive independent, blinded biomechanical gait analyses demonstrating genuine neural recovery with NVG-291 in the Phase 1b/2a CONNECT SCI study.
MONTREAL, April 15, 2026 /PRNewswire/ -- Vision Marine Technologies Inc. (NASDAQ: VMAR) ("Vision Marine" or the "Company"), a company specializing in high-voltage marine propulsion and a vertically integrated marine retail platform, yesterday reported financial results for the three-month and six-month periods ended February 28, 2026, highlighting rapid execution and significant operational improvements across its Nautical Ventures Group Inc. ("NVG") platform. Since the acquisition of NVG on June 20, 2025, the Company has delivered substantial improvements in working capital efficiency, leverage reduction, and operating performance, positioning NVG near EBITDA breakeven within less than one year of integration.
VANCOUVER, British Columbia, April 07, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the completion of a successful End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) and alignment on RESTORE, the Company's Phase 3 registrational study designed to evaluate NVG-291 for the treatment of chronic tetraplegia.
Rivernorth Capital Management reduced Nuveen AMT-Free Municipal Credit Income Fund (NVG) position by 2,033,953 shares Quarter-end position value decreased by $24.89 million, reflecting both trading and price movement Transaction represented approximately 1.21% of Rivernorth's 13F AUM Post-trade stake: 280,382 shares valued at $3.55 million The holding now represents 0.17% of AUM, placing it outside the fund's top five holdings
I increased exposure to municipal bond CEFs, adding Nuveen AMT-Free Municipal Credit Income Fund and Nuveen Municipal Credit Income Fund for higher yields. NXP remains a core holding for its high quality, low leverage, and investment-grade focus, contrasting with NVG and NZF's higher yield and risk profiles. NVG and NZF deploy over 40% leverage and hold 74–75% investment-grade bonds, with notable exposure to Illinois, Texas, and California.